Glycemic control

A short period of intermittently scanned continuous glucose monitoring prior to a first endocrinologist consultation can improve glycemic outcomes for people with type 2 diabetes, report the SPOT FIRST study researchers.

Empagliflozin, but not linagliptin, provides “clinically relevant” improvements in glycemic control versus placebo in children and adolescents with type 2 diabetes, report the DINAMO investigators.

A randomised trial shows that use of a prebiotic fibre-enriched nutritional formula results in improved life quality and, potentially, better glycaemic control in people with type 2 diabetes.

Randomized trial findings show reduced glycated hemoglobin and bodyweight in people with type 2 diabetes following a calorie-unrestricted low-carbohydrate, high-fat diet versus a high-carbohydrate, low-fat approach.

An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.

Findings from a randomized controlled trial published in Diabetes Care suggest that for people with type 2 diabetes, the delivery of cognitive behavioral therapy via a digital therapeutic app, on top of standard of care, may reduce glycated hemoglobin.

Age, duration of type 2 diabetes, and race may help guide choice of glucose-lowering therapy for individuals with established CVD or those at high risk, say the authors of a systematic review and meta-analysis published in eClinicalMedicine.